Jason Kato

467 total citations
8 papers, 389 citations indexed

About

Jason Kato is a scholar working on Oncology, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, Jason Kato has authored 8 papers receiving a total of 389 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Oncology, 4 papers in Molecular Biology and 4 papers in Pathology and Forensic Medicine. Recurrent topics in Jason Kato's work include Lymphoma Diagnosis and Treatment (4 papers), Monoclonal and Polyclonal Antibodies Research (3 papers) and CAR-T cell therapy research (3 papers). Jason Kato is often cited by papers focused on Lymphoma Diagnosis and Treatment (4 papers), Monoclonal and Polyclonal Antibodies Research (3 papers) and CAR-T cell therapy research (3 papers). Jason Kato collaborates with scholars based in United States, Taiwan and India. Jason Kato's co-authors include Juntao Luo, Kai Xiao, Yuanpei Li, Kit S. Lam, Joyce Lee, Abby M. Gonik, Wenwu Xiao, Tiffany Dong, Robert T. OʼDonnell and Joseph M. Tuscano and has published in prestigious journals such as Biomaterials, Cancer Research and Molecular Pharmaceutics.

In The Last Decade

Jason Kato

8 papers receiving 384 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jason Kato United States 7 223 156 141 77 71 8 389
Hemda Baabur‐Cohen Israel 7 295 1.3× 188 1.2× 189 1.3× 65 0.8× 63 0.9× 8 500
Fabiana Canal Spain 7 329 1.5× 205 1.3× 176 1.2× 114 1.5× 70 1.0× 8 514
Eva Randárová Czechia 13 258 1.2× 134 0.9× 194 1.4× 97 1.3× 60 0.8× 29 432
Aida Varela-Moreira Netherlands 12 274 1.2× 202 1.3× 149 1.1× 77 1.0× 38 0.5× 16 507
Juan J. Arroyo‐Crespo Spain 7 164 0.7× 150 1.0× 140 1.0× 50 0.6× 30 0.4× 9 366
Ebel H. E. Pieters Netherlands 10 346 1.6× 243 1.6× 200 1.4× 102 1.3× 60 0.8× 11 593
Hao-jui Hsu United States 10 191 0.9× 242 1.6× 118 0.8× 64 0.8× 165 2.3× 11 431
Hayley Nehoff New Zealand 3 272 1.2× 165 1.1× 221 1.6× 37 0.5× 30 0.4× 3 466
Shyam M. Garg Canada 7 221 1.0× 136 0.9× 93 0.7× 145 1.9× 53 0.7× 7 385
Mary Mehlig United States 7 164 0.7× 299 1.9× 99 0.7× 60 0.8× 42 0.6× 9 473

Countries citing papers authored by Jason Kato

Since Specialization
Citations

This map shows the geographic impact of Jason Kato's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jason Kato with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jason Kato more than expected).

Fields of papers citing papers by Jason Kato

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jason Kato. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jason Kato. The network helps show where Jason Kato may publish in the future.

Co-authorship network of co-authors of Jason Kato

This figure shows the co-authorship network connecting the top 25 collaborators of Jason Kato. A scholar is included among the top collaborators of Jason Kato based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jason Kato. Jason Kato is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
1.
Kato, Jason, et al.. (2016). The HB22.7–vcMMAE antibody–drug conjugate has efficacy against non-Hodgkin lymphoma mouse xenografts with minimal systemic toxicity. Cancer Immunology Immunotherapy. 65(10). 1169–1175. 6 indexed citations
2.
Wu, Chun‐Yi, Xiaobing Wang, Liping Meng, et al.. (2016). Rapid Discovery of Functional Small Molecule Ligands against Proteomic Targets through Library-Against-Library Screening. ACS Combinatorial Science. 18(6). 320–329. 8 indexed citations
3.
Kato, Jason, et al.. (2012). Efficacy of a CD22-targeted antibody-saporin conjugate in a xenograft model of precursor-B cell acute lymphoblastic leukemia. Leukemia Research. 37(1). 83–88. 11 indexed citations
4.
Kato, Jason, Yuanpei Li, Kai Xiao, et al.. (2012). Disulfide Cross-Linked Micelles for the Targeted Delivery of Vincristine to B-Cell Lymphoma. Molecular Pharmaceutics. 9(6). 1727–1735. 44 indexed citations
5.
Kato, Jason, et al.. (2012). Efficacy and toxicity of a CD22-targeted antibody-saporin conjugate in a xenograft model of non-Hodgkin’s lymphoma. OncoImmunology. 1(9). 1469–1475. 12 indexed citations
6.
Tuscano, Joseph M., Jason Kato, David Pearson, et al.. (2012). CD22 Antigen Is Broadly Expressed on Lung Cancer Cells and Is a Target for Antibody-Based Therapy. Cancer Research. 72(21). 5556–5565. 26 indexed citations
7.
Tuscano, Joseph M., et al.. (2011). The Bs20x22 anti-CD20-CD22 bispecific antibody has more lymphomacidal activity than do the parent antibodies alone. Cancer Immunology Immunotherapy. 60(6). 771–780. 12 indexed citations
8.
Li, Yuanpei, Kai Xiao, Juntao Luo, et al.. (2011). Well-defined, reversible disulfide cross-linked micelles for on-demand paclitaxel delivery. Biomaterials. 32(27). 6633–6645. 270 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026